TYRA BIOSCIENCES INC (TYRA)
US90240B1061 - Common Stock
TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023
TYRA stock results show that Tyra Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tyra Biosciences (NASDAQ:TYRA) just reported results for the fourth quarter of ...
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences to Present at Upcoming Investor Conferences
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences stock rises on $200M private financing
Tyra Biosciences (TYRA) surges after announcing a $200M private placement financing deal led by RA Capital Management. Read mroe here.
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra gets FDA Rare Pediatric Disease status for dwarfism drug (NASDAQ:TYRA)
Tyra Biosciences (TYRA) said the FDA has granted Rare Pediatric Disease Designation to its drug candidate TYRA-300 in the treatment of dwarfism. Read more here.
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Commit To Purchase Tyra Biosciences At $7.50, Earn 10.9% Annualized Using Options
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences Becomes Oversold (TYRA)
Commit To Purchase Tyra Biosciences At $12.50, Earn 37.6% Annualized Using Options
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences gets FDA orphan drug designation for dwarfism therapy (NASDAQ:TYRA)
Tyra Biosciences (TYRA) said the FDA has granted orphan drug status to its lead drug candidate TYRA-300 for achondroplasia, a common form of dwarfism. Read more here.
Tyra Biosciences to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
(NASDAQ:TYRA)
Tyra Biosciences press release (TYRA): Q4 GAAP EPS of -$0.31 beats by $0.05.Alan Fuhrman, CFO of TYRA, added, "TYRA is in a very strong financial position to begin 2023, with...
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Friday Sector Laggards: Biotechnology, Drugs
Tyra Biosciences to Present at Upcoming Investor Conferences
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance...